IDEXX Laboratories, Inc. $IDXX Stock Sold by Acima Private Wealth LLC

Acima Private Wealth LLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 69.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 449 shares of the company’s stock after selling 1,038 shares during the period. Acima Private Wealth LLC’s holdings in IDEXX Laboratories were worth $234,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Triad Wealth Partners LLC increased its position in IDEXX Laboratories by 3.1% during the first quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock worth $337,000 after buying an additional 18 shares in the last quarter. KCM Investment Advisors LLC lifted its position in shares of IDEXX Laboratories by 5.3% in the fourth quarter. KCM Investment Advisors LLC now owns 377 shares of the company’s stock valued at $255,000 after acquiring an additional 19 shares in the last quarter. Arlington Trust Co LLC lifted its position in shares of IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after acquiring an additional 19 shares in the last quarter. Evolve Private Wealth LLC boosted its stake in shares of IDEXX Laboratories by 3.2% during the first quarter. Evolve Private Wealth LLC now owns 640 shares of the company’s stock valued at $360,000 after acquiring an additional 20 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC boosted its stake in shares of IDEXX Laboratories by 21.4% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock valued at $67,000 after acquiring an additional 21 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Trading Up 1.7%

Shares of IDXX traded up $8.68 during mid-day trading on Monday, hitting $527.07. The company had a trading volume of 588,911 shares, compared to its average volume of 569,073. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98. The business’s 50-day simple moving average is $543.61 and its 200-day simple moving average is $555.14. The stock has a market cap of $41.52 billion, a PE ratio of 37.07, a P/E/G ratio of 2.77 and a beta of 1.55. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping the consensus estimate of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. UBS Group boosted their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Barclays cut their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Finally, Citigroup upped their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.